Technical Analysis for IMM - Immupharma Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Historical IMM trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | -8.61% | |
| 20 DMA Support | Bullish | -8.61% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -8.61% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -8.61% | |
| Outside Day | Range Expansion | -8.61% | |
| Boomer Buy Setup | Bullish Swing Setup | -6.76% | |
| Narrow Range Bar | Range Contraction | -6.76% | |
| NR7 | Range Contraction | -6.76% | |
| NR7-2 | Range Contraction | -6.76% | |
| Inside Day | Range Contraction | -6.76% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
| 20 DMA Support | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
Get this analysis on your stocks daily!
Immupharma Plc Description
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Clinic Cement Disease Earl Cancer Medical Specialties Diseases Drugs Mr Drug Discovery Autoimmune Diseases Disorders Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 13.079 |
| 52 Week Low | 4.8 |
| Average Volume | 968,478 |
| 200-Day Moving Average | 7.89 |
| 50-Day Moving Average | 6.63 |
| 20-Day Moving Average | 7.08 |
| 10-Day Moving Average | 7.37 |
| Average True Range | 0.88 |
| ADX | 38.86 |
| +DI | 21.11 |
| -DI | 5.45 |
| Chandelier Exit (Long, 3 ATRs) | 5.84 |
| Chandelier Exit (Short, 3 ATRs) | 7.94 |
| Upper Bollinger Bands | 8.06 |
| Lower Bollinger Band | 6.11 |
| Percent B (%b) | 0.74 |
| BandWidth | 27.58 |
| MACD Line | 0.30 |
| MACD Signal Line | 0.25 |
| MACD Histogram | 0.049 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.99 | ||||
| Resistance 3 (R3) | 8.97 | 8.46 | 8.75 | ||
| Resistance 2 (R2) | 8.46 | 8.10 | 8.48 | 8.67 | |
| Resistance 1 (R1) | 8.01 | 7.87 | 7.76 | 8.03 | 8.59 |
| Pivot Point | 7.50 | 7.50 | 7.38 | 7.52 | 7.50 |
| Support 1 (S1) | 7.05 | 7.14 | 6.80 | 7.07 | 6.51 |
| Support 2 (S2) | 6.54 | 6.91 | 6.56 | 6.43 | |
| Support 3 (S3) | 6.09 | 6.54 | 6.35 | ||
| Support 4 (S4) | 6.11 |
